← Return to Prostate Biopsy Complication

Discussion

Prostate Biopsy Complication

Prostate Cancer | Last Active: 4 days ago | Replies (32)
Comment receiving replies
@handera

The MPS2 test was approved for Medicare coverage in September 2024.

“The coverage determination means that patients meeting the policy criteria—those at risk for prostate cancer and candidates for either an initial or repeat biopsy—will now have access to MPS2 under their Medicare plans.”
https://www.lynxdx.com/2024/11/news/my-prostate-score-medicare-coverage/

Jump to this post

Replies to "The MPS2 test was approved for Medicare coverage in September 2024. “The coverage determination means that..."
handera | @handera | 5 days ago

The MPS2 test achieves 95-99% sensitivity and negative predictive value, making it highly reliable in ruling out significant cancers.

However, its specificity for detecting clinically significant prostate cancer (Grade Group ≥2) is approximately 80% at the rule-in threshold. This means about 20% of positive results could be false positives.
https://www.nature.com/articles/s41391-022-00633-3

VIEW AND REPLY